No price history available.
Key financial summary
Financials in ILA| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ILAm | 96 | 206 | 173 | 172 | 218 | 263 | N/A | N/A |
| Operating profit | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ILAm | 3 | 11 | 23 | 16 | 7 | 19 | N/A | N/A |
| EPS reported | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in ILA| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Aran Research & Development (1982) Ltd., an Israeli company founded in Caesarea in 1982, specializes in the design, development, and manufacturing of various products and equipment, with a significant focus on the plastics industry within Israel. The company boasts a broad portfolio, encompassing a wide array of medical devices such as cardiovascular solutions, in-vitro diagnostic tools, surgical instruments, and advanced imaging and monitoring systems. They are also prominent in fluid management, producing water devices like pressure and flow regulators, a variety of valves (electric, hydraulic, air release, check), sprinklers, drippers, taps, water meters, filters, electronic controllers, and specialized testing equipment. Beyond these core areas, Aran provides portable and stationary control systems for unmanned platforms, electro-optical technologies, and robust electronic hardware engineered for demanding ground, marine, and aerial environments. Their offerings extend to ground systems for security and access control, test and measurement equipment, and production line facilities. The company further manufactures specialized printers, automatic beverage dispensers, sophisticated retail technology like computerized shopping carts and self-checkout kiosks, industrial and communication devices, and batteries. Additionally, Aran acts as a supplier for crucial machinery and components, including injection molding machines, robotics and automation systems, injection molds, hot runner systems, drying, dosing, and conveying systems, plasticizing screws and barrels, and ultrasonic welding and cleaning equipment, along with raw materials. The firm also delivers comprehensive support services and makes strategic investments in emerging medical technology startups.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Aran Research & Development (1982) Ltd. (ARAN.TA)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Aran Research & Development (1982) Ltd., an Israeli company founded in Caesarea in 1982, specializes in the design, development, and manufacturing of various products and equipment, with a significant focus on the plastics industry within Israel. The company boasts a broad portfolio, encompassing a wide array of medical devices such as cardiovascular solutions, in-vitro diagnostic tools, surgical instruments, and advanced imaging and monitoring systems. They are also prominent in fluid management, producing water devices like pressure and flow regulators, a variety of valves (electric, hydraulic, air release, check), sprinklers, drippers, taps, water meters, filters, electronic controllers, and specialized testing equipment. Beyond these core areas, Aran provides portable and stationary control systems for unmanned platforms, electro-optical technologies, and robust electronic hardware engineered for demanding ground, marine, and aerial environments. Their offerings extend to ground systems for security and access control, test and measurement equipment, and production line facilities. The company further manufactures specialized printers, automatic beverage dispensers, sophisticated retail technology like computerized shopping carts and self-checkout kiosks, industrial and communication devices, and batteries. Additionally, Aran acts as a supplier for crucial machinery and components, including injection molding machines, robotics and automation systems, injection molds, hot runner systems, drying, dosing, and conveying systems, plasticizing screws and barrels, and ultrasonic welding and cleaning equipment, along with raw materials. The firm also delivers comprehensive support services and makes strategic investments in emerging medical technology startups.
